Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone

被引:3
|
作者
da Silva, Eveline Santos [1 ]
Servais, Jean-Yves [1 ]
Kohnen, Michel [2 ]
Arendt, Victor [2 ]
Gilson, Georges [2 ]
Staub, Therese [2 ]
Seguin-Devaux, Carole [1 ]
Perez-Bercoff, Danielle [1 ]
机构
[1] Luxembourg Inst Hlth, Dept Infect & Immun, HIV Clin & Translat Res Unit, 29 Rue Henri Koch, L-4354 Esch Sur Alzette, Luxembourg
[2] Ctr Hosp Luxembourg, 4 Rue Ernest Barble, L-1210 Luxembourg, Luxembourg
关键词
SARS-CoV-2; neutralization; vaccination; hybrid immunity; breakthrough infection; Omicron BA; 1; BA; 2; 4; 5; IMMUNODEFICIENCY-VIRUS TYPE-1; SARS-COV-2; OMICRON; CONVALESCENT; MATURATION; ANTIBODIES; RESISTANCE; BREADTH; POTENCY;
D O I
10.3390/cimb45020112
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since the emergence of SARS-CoV-2 Omicron BA.1 and BA.2, several Omicron sublineages have emerged, supplanting their predecessors. Here we compared the neutralization of Omicron sublineages BA.1, BA.2, BA.4 and BA.5 by human sera collected from individuals who were infected with the ancestral B.1 (D614G) strain, who were vaccinated (3 doses) or with breakthrough infection with pre-Omicron strains (Gamma or Delta). All Omicron sublineages exhibited extensive escape from all sera when compared to the ancestral B.1 strain and to Delta, albeit to different levels depending on the origin of the sera. Convalescent sera were unable to neutralize BA.1, and partly neutralized BA.2, BA.4 and BA.5. Vaccinee sera partly neutralized BA.2, but BA.1, BA.4 and BA.5 evaded neutralizing antibodies (NAb). Some breakthrough infections (BTI) sera were non-neutralizing. Neutralizing BTI sera had similar neutralizing ability against all Omicron sublineages. Despite similar levels of anti-Spike and anti-Receptor Binding Domain (RBD) antibodies in all groups, BTI sera had the highest cross-neutralizing ability against all Omicron sublineages and convalescent sera were the least neutralizing. Antibody avidity inferred from the NT50:antibody titer ratio was highest in sera from BTI patients, underscoring qualitative differences in antibodies elicited by infection or vaccination. Together, these findings highlight the importance of vaccination to trigger highly cross-reactive antibodies that neutralize phylogenetically and antigenically distant strains, and suggest that immune imprinting by first generation vaccines may restrict, but not abolish, cross-neutralization.
引用
收藏
页码:1741 / 1761
页数:21
相关论文
共 50 条
  • [31] A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
    Chen, Zhe
    Feng, Leilei
    Wang, Lei
    Zhang, Li
    Zheng, Binyang
    Fu, Hua
    Li, Fengdi
    Liu, Ligai
    Lv, Qi
    Deng, Ran
    Xu, Yanli
    Hu, Yongfeng
    Zheng, Jianhua
    Qin, Chuan
    Bao, Linlin
    Wang, Xiangxi
    Jin, Qi
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [32] Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccineexperienced humans and mice
    Muik, Alexander
    Lui, Bonny Gaby
    Bacher, Maren
    Wallisch, Ann-Kathrin
    Toker, Aras
    Couto, Carla Iris Cadima
    Gueler, Alptekin
    Mampilli, Veena
    Schmitt, Geneva J.
    Mottl, Jonathan
    Ziegenhals, Thomas
    Fesser, Stephanie
    Reinholz, Jonas
    Wernig, Florian
    Schraut, Karla-Gerlinde
    Hefesha, Hossam
    Cai, Hui
    Yang, Qi
    Walzer, Kerstin C.
    Grosser, Jessica
    Strauss, Stefan
    Finlayson, Andrew
    Kruger, Kimberly
    Ozhelvaci, Orkun
    Grikscheit, Katharina
    Kohmer, Niko
    Ciesek, Sandra
    Swanson, Kena A.
    Vogel, Annette B.
    Tuereci, Oezlem
    Sahin, Ugur
    SCIENCE IMMUNOLOGY, 2022, 7 (78)
  • [33] Estimated Effectiveness of Prior SARS-CoV-2 BA.1 or BA.2 Infection and Booster Vaccination Against Omicron BA.5 Subvariant Infection
    Jang, Eun Jung
    Choe, Young June
    Kim, Ryu Kyung
    Lee, Sangwon
    Park, Seon Kyeong
    Park, Young-Joon
    JAMA NETWORK OPEN, 2023, 6 (03) : E232578
  • [34] Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
    Tomokazu Tamura
    Daichi Yamasoba
    Yoshitaka Oda
    Jumpei Ito
    Tomoko Kamasaki
    Naganori Nao
    Rina Hashimoto
    Yoichiro Fujioka
    Rigel Suzuki
    Lei Wang
    Hayato Ito
    Yukie Kashima
    Izumi Kimura
    Mai Kishimoto
    Masumi Tsuda
    Hirofumi Sawa
    Kumiko Yoshimatsu
    Yuki Yamamoto
    Tetsuharu Nagamoto
    Jun Kanamune
    Yutaka Suzuki
    Yusuke Ohba
    Isao Yokota
    Keita Matsuno
    Kazuo Takayama
    Shinya Tanaka
    Kei Sato
    Takasuke Fukuhara
    Communications Biology, 6
  • [35] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
    Tseng, Hung Fu
    Ackerson, Bradley K.
    Bruxvoort, Katia J.
    Sy, Lina S.
    Tubert, Julia E.
    Lee, Gina S.
    Ku, Jennifer H.
    Florea, Ana
    Luo, Yi
    Qiu, Sijia
    Choi, Soon Kyu
    Takhar, Harpreet S.
    Aragones, Michael
    Paila, Yamuna D.
    Chavers, Scott
    Talarico, Carla A.
    Qian, Lei
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [36] Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
    Hung Fu Tseng
    Bradley K. Ackerson
    Katia J. Bruxvoort
    Lina S. Sy
    Julia E. Tubert
    Gina S. Lee
    Jennifer H. Ku
    Ana Florea
    Yi Luo
    Sijia Qiu
    Soon Kyu Choi
    Harpreet S. Takhar
    Michael Aragones
    Yamuna D. Paila
    Scott Chavers
    Carla A. Talarico
    Lei Qian
    Nature Communications, 14
  • [37] Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
    Tamura, Tomokazu
    Yamasoba, Daichi
    Oda, Yoshitaka
    Ito, Jumpei
    Kamasaki, Tomoko
    Nao, Naganori
    Hashimoto, Rina
    Fujioka, Yoichiro
    Suzuki, Rigel
    Wang, Lei
    Ito, Hayato
    Kashima, Yukie
    Kimura, Izumi
    Kishimoto, Mai
    Tsuda, Masumi
    Sawa, Hirofumi
    Yoshimatsu, Kumiko
    Yamamoto, Yuki
    Nagamoto, Tetsuharu
    Kanamune, Jun
    Suzuki, Yutaka
    Ohba, Yusuke
    Tabata, Kaori
    Yokota, Isao
    Matsuno, Keita
    Takayama, Kazuo
    Tanaka, Shinya
    Sato, Kei
    Fukuhara, Takasuke
    COMMUNICATIONS BIOLOGY, 2023, 6 (01)
  • [38] Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa
    Wolter, Nicole
    Jassat, Waasila
    von Gottberg, Anne
    Cohen, Cheryl
    LANCET, 2022, 400 (10346): : 93 - 96
  • [39] Humoral and cellular immune responses following Omicron BA.2.2 breakthrough infection and Omicron BA.5 reinfection
    Zhao, Xin-Jing
    Ji, Bin
    Shang, Chao
    Li, De-Yu
    Zhang, Sheng
    Gu, Hong-Jing
    Peng, Hong-Hong
    Qian, Cheng
    Zhang, Cui-Ling
    Shi, Chao
    Shen, Yuan
    Chen, Jin-Jin
    Xu, Qiang
    Lv, Chen-Long
    Jiang, Bao-Gui
    Wang, Hui
    Li, Xiao
    Wang, Guo-Lin
    Fang, Li-Qun
    ISCIENCE, 2024, 27 (07)
  • [40] Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study
    Kang, Sung-Woon
    Park, Heedo
    Kim, Ji Yeun
    Lim, So Yun
    Lee, Sohyun
    Bae, Joon-Yong
    Kim, Jeonghun
    Chang, Euijin
    Bae, Seongman
    Jung, Jiwon
    Kim, Min Jae
    Chong, Yong Pil
    Lee, Sang-Oh
    Choi, Sang-Ho
    Kim, Yang Soo
    Park, Man-Seong
    Kim, Sung-Han
    JOURNAL OF INFECTION, 2023, 86 (05) : e148 - e151